Back to Journals » Clinical Interventions in Aging » Volume 3 » Issue 1

HT update: spotlight on estradiol/norethindrone acetate combination therapy

Authors Casey CL, Murray CA

Published 7 March 2008 Volume 2008:3(1) Pages 9—16

DOI https://doi.org/10.2147/CIA.S1663


Colleen L Casey, Christine A Murray

University of Vermont, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Burlington, VT, USA

Abstract: The goal of postmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.

Keywords: postmenopausal hormone therapy, norethindrone acetate, estradiol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]